Merck's Stock Gains Momentum as Oncology Pipeline Expands

Merck's (MRK) stock has seen significant gains in recent months, driven by promising results from a Phase 3 study of its intismeran autogene with Keytruda in melanoma patients. The trial met its primary endpoints, demonstrating meaningful clinical benefits and potentially reshaping the stock's long-term prospects.

The company's oncology pipeline has seen significant growth since 2021, thanks to its acquisition and licensing strategy. This expansion is expected to drive earnings growth and provide a potential commercial opportunity of over $50 billion by the mid-2030s.

Despite the stock's recent surge, it still trades at a discount to some intrinsic value estimates, with an average analyst target slightly above the current price. However, the Simply Wall Street DCF model suggests that Merck is actually undervalued, trading around 34.3% below its estimated future cash flow value of $232.91.